Sivia Capital Partners LLC Purchases 262 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Sivia Capital Partners LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.9% during the first quarter, Holdings Channel reports. The firm owned 3,580 shares of the biopharmaceutical company’s stock after acquiring an additional 262 shares during the period. Sivia Capital Partners LLC’s holdings in Gilead Sciences were worth $401,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in GILD. Brighton Jones LLC lifted its position in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares in the last quarter. GHP Investment Advisors Inc. lifted its position in shares of Gilead Sciences by 1.1% during the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock valued at $1,049,000 after purchasing an additional 122 shares in the last quarter. Strategic Financial Concepts LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $6,640,000. Golden State Wealth Management LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $70,000. Finally, NatWest Group plc bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $6,808,000. 83.67% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now directly owns 620,268 shares in the company, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the transaction, the insider now owns 121,152 shares of the company’s stock, valued at $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,929 shares of company stock worth $6,748,980. 0.27% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. BMO Capital Markets raised their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective for the company. Morgan Stanley raised their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, April 25th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $110.55.

Gilead Sciences Price Performance

GILD opened at $112.46 on Friday. The company has a market capitalization of $139.89 billion, a price-to-earnings ratio of 303.95, a PEG ratio of 0.71 and a beta of 0.29. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a 50-day moving average price of $105.39 and a 200-day moving average price of $101.56. Gilead Sciences, Inc. has a twelve month low of $62.69 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the business earned ($1.32) earnings per share. Gilead Sciences’s revenue was down .3% compared to the same quarter last year. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.81%. Gilead Sciences’s dividend payout ratio (DPR) is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.